Bellevue Group AG Increases Stock Position in SI-BONE, Inc. (NASDAQ:SIBN)

Bellevue Group AG grew its stake in shares of SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 4.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,444,109 shares of the company's stock after acquiring an additional 56,500 shares during the quarter. Bellevue Group AG owned about 3.46% of SI-BONE worth $20,189,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. Champlain Investment Partners LLC lifted its holdings in shares of SI-BONE by 14.7% during the third quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company's stock valued at $39,145,000 after purchasing an additional 358,821 shares in the last quarter. Vanguard Group Inc. raised its stake in SI-BONE by 1.8% during the 1st quarter. Vanguard Group Inc. now owns 2,463,501 shares of the company's stock worth $40,328,000 after acquiring an additional 43,670 shares during the period. American Century Companies Inc. raised its position in shares of SI-BONE by 22.8% during the 2nd quarter. American Century Companies Inc. now owns 1,986,476 shares of the company's stock valued at $25,685,000 after purchasing an additional 368,637 shares during the period. Paradigm Capital Management Inc. NY lifted its position in shares of SI-BONE by 24.7% in the second quarter. Paradigm Capital Management Inc. NY now owns 1,349,400 shares of the company's stock valued at $17,448,000 after acquiring an additional 267,100 shares in the last quarter. Finally, Impax Asset Management Group plc lifted its holdings in SI-BONE by 41.3% in the 3rd quarter. Impax Asset Management Group plc now owns 758,521 shares of the company's stock worth $10,604,000 after purchasing an additional 221,604 shares in the last quarter. Hedge funds and other institutional investors own 98.11% of the company's stock.

Insider Transactions at SI-BONE

In other news, CFO Anshul Maheshwari sold 2,439 shares of the firm's stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $12.68, for a total transaction of $30,926.52. Following the transaction, the chief financial officer now directly owns 194,623 shares of the company's stock, valued at approximately $2,467,819.64. This trade represents a 1.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Laura Francis sold 10,048 shares of the business's stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $12.58, for a total value of $126,403.84. Following the completion of the sale, the chief executive officer now owns 482,875 shares of the company's stock, valued at $6,074,567.50. The trade was a 2.04 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,093 shares of company stock worth $299,558. 3.90% of the stock is currently owned by insiders.

SI-BONE Trading Up 2.2 %

SIBN traded up $0.29 during trading on Friday, reaching $13.56. The company had a trading volume of 147,807 shares, compared to its average volume of 409,928. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22. The business has a 50 day simple moving average of $13.48 and a 200-day simple moving average of $14.14. The stock has a market cap of $568.71 million, a P/E ratio of -14.74 and a beta of 1.22. SI-BONE, Inc. has a 52 week low of $11.70 and a 52 week high of $21.70.

Analysts Set New Price Targets

Several brokerages have commented on SIBN. Truist Financial boosted their price target on shares of SI-BONE from $16.00 to $18.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. Needham & Company LLC reiterated a "buy" rating and issued a $19.00 target price on shares of SI-BONE in a research report on Wednesday, November 20th. Finally, Morgan Stanley cut their price target on SI-BONE from $21.00 to $19.00 and set an "overweight" rating for the company in a report on Tuesday, August 6th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $23.00.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.